2000
DOI: 10.1097/00006231-200006000-00078
|View full text |Cite
|
Sign up to set email alerts
|

Biodistribution and dosimetry of 99mTc RP527, a gastrin releasing peptide agonist for the visualisation of GRP-receptor expressing malignancies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

4
78
0
2

Year Published

2002
2002
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 56 publications
(84 citation statements)
references
References 0 publications
4
78
0
2
Order By: Relevance
“…However, similar strategies have been used for years in the field of positron emission tomography (PET), which often involves incorporation of a radioactive nucleus into a ligand of interest shortly before administration to a patient. For example, biological peptides of interest bearing artificial amino acid side-chains as chelating groups can be ''tagged'' with positron-emitting isotopes such as technecium-99 and delivered to a patient (23,24). These labeled tracers can then be assessed in vivo, using a gamma camera.…”
Section: Discussionmentioning
confidence: 99%
“…However, similar strategies have been used for years in the field of positron emission tomography (PET), which often involves incorporation of a radioactive nucleus into a ligand of interest shortly before administration to a patient. For example, biological peptides of interest bearing artificial amino acid side-chains as chelating groups can be ''tagged'' with positron-emitting isotopes such as technecium-99 and delivered to a patient (23,24). These labeled tracers can then be assessed in vivo, using a gamma camera.…”
Section: Discussionmentioning
confidence: 99%
“…For example, 99m Tcand 111 In-coupled BN analogues have been developed for diagnostic SPECT imaging and 64 Cu-and 68 Ga-labelled analogues for PET imaging of GRP receptor-expressing tumours [26][27][28][29][30][31][32][33][34][35][36][37][38][39]. In addition, 90 Y-and 177 Lu-labelled analogues have been described as promising tools for targeted radiotherapy of these tumours [26,40].…”
mentioning
confidence: 99%
“…In fact, there have been various radiolabeled bombesin conjugates containing extensive modifications to the N-terminus, which still retain high affinity for the desired receptors (Baidoo et al 1998;La Bella et al 2002;Smith et al 2003; Van de Wiele et al 2001). Consequently, most labeled bombesin analogs are simply modifications of this bombesin-(7-14) sequence (Baidoo et al 1998;La Bella et al 2002;Smith et al 2003; Van de Wiele et al 2001; Van de Wiele et al 2000). In this case, modification of the bombesin-(7-14) peptide was carried out to include a second β-alanine extension in position six, replacing the non-essential D-Tyr (Fig.…”
Section: Peptide Synthesismentioning
confidence: 99%